Recent Finacing
Recent Raise
CatalYm develops visugromab (CTL‑002), a humanized monoclonal antibody that neutralizes tumor‑derived GDF‑15 to reverse immune suppression and enhance anti‑PD‑1 responses in solid tumor Phase 2 programs.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at CatalYm.
